MDP vs. OGI, SUGR, FIRE, EPI, ICC, RIV, LEAF, HLS, RX, and CRDL
Should you be buying Medexus Pharmaceuticals stock or one of its competitors? The main competitors of Medexus Pharmaceuticals include Organigram (OGI), SugarBud Craft Growers (SUGR), Supreme Cannabis (FIRE), ESSA Pharma (EPI), ICC Labs (ICC), RIV Capital (RIV), Leaf Mobile (LEAF), HLS Therapeutics (HLS), BioSyent (RX), and Cardiol Therapeutics (CRDL). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Medexus Pharmaceuticals vs. Its Competitors
Medexus Pharmaceuticals (TSE:MDP) and Organigram (TSE:OGI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.
Medexus Pharmaceuticals has a net margin of 3.25% compared to Organigram's net margin of -31.69%. Medexus Pharmaceuticals' return on equity of 11.07% beat Organigram's return on equity.
In the previous week, Organigram had 2 more articles in the media than Medexus Pharmaceuticals. MarketBeat recorded 2 mentions for Organigram and 0 mentions for Medexus Pharmaceuticals. Organigram's average media sentiment score of 0.59 beat Medexus Pharmaceuticals' score of 0.00 indicating that Organigram is being referred to more favorably in the news media.
Medexus Pharmaceuticals has higher earnings, but lower revenue than Organigram. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than Organigram, indicating that it is currently the more affordable of the two stocks.
Medexus Pharmaceuticals currently has a consensus target price of C$4.57, suggesting a potential upside of 66.06%. Organigram has a consensus target price of C$3.33, suggesting a potential upside of 36.83%. Given Medexus Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Medexus Pharmaceuticals is more favorable than Organigram.
Medexus Pharmaceuticals has a beta of 1.598909, suggesting that its stock price is 60% more volatile than the S&P 500. Comparatively, Organigram has a beta of 2.185402, suggesting that its stock price is 119% more volatile than the S&P 500.
0.8% of Medexus Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.2% of Organigram shares are owned by institutional investors. 9.1% of Medexus Pharmaceuticals shares are owned by insiders. Comparatively, 31.3% of Organigram shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Medexus Pharmaceuticals and Organigram tied by winning 8 of the 16 factors compared between the two stocks.
Get Medexus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Medexus Pharmaceuticals Competitors List
Related Companies and Tools
This page (TSE:MDP) was last updated on 10/21/2025 by MarketBeat.com Staff